Rare expression of KIT (CD117) in lymphomas

A tissue microarray study of 1166 cases

A. Zimpfer, P. Went, A. Tzankov, A. C. Pehrs, A. Lugli, R. Maurer, L. Terracciano, S. Pileri, Stephan Dirnhofer

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Aims: Imatinib mesylate specifically inhibits KIT tyrosine kinase activity, and has been proven to be effective in the treatment of gastrointestinal stromal tumours. Because other KIT-expressing malignancies might benefit from Imatinib therapy, we evaluated the distribution and expression of KIT in 1166 cases of malignant lymphoma. Materials and results: Tissue microarrays (TMAs) containing 824 non-Hodgkin's lymphoma (NHL) and 342 Hodgkin's lymphoma (HL) cases were immunohistochemically analysed for the expression of the KIT protein. Two KIT-positive NHLs were sequenced using polymerase chain reaction analysis. One T-cell lymphoma and one follicular lymphoma of the 747 NHL cases (0.3%) were positive for KIT. All HLs were Kit-negative. None of the KIT-positive cases showed a kit gene mutation. Conclusions: KIT expression is a very rare event in NHL and virtually absent in HL. In the few positive cases, the aberrant expression is not caused by a mutation in the 'hot-spots' of the kit gene, indicating that treatment of these tumours with Imatinib may be ineffective.

Original languageEnglish
Pages (from-to)398-404
Number of pages7
JournalHistopathology
Volume45
Issue number4
DOIs
Publication statusPublished - Oct 2004

Fingerprint

Non-Hodgkin's Lymphoma
Lymphoma
Hodgkin Disease
Mutation
Follicular Lymphoma
Gastrointestinal Stromal Tumors
T-Cell Lymphoma
Protein-Tyrosine Kinases
Genes
Neoplasms
Polymerase Chain Reaction
Imatinib Mesylate
Proteins
Therapeutics

Keywords

  • CD117
  • Hodgkin's lymphoma
  • KIT
  • Non-Hodgkin's lymphoma
  • Tissue microarray

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Cell Biology

Cite this

Zimpfer, A., Went, P., Tzankov, A., Pehrs, A. C., Lugli, A., Maurer, R., ... Dirnhofer, S. (2004). Rare expression of KIT (CD117) in lymphomas: A tissue microarray study of 1166 cases. Histopathology, 45(4), 398-404. https://doi.org/10.1111/j.1365-2559.2004.01968.x

Rare expression of KIT (CD117) in lymphomas : A tissue microarray study of 1166 cases. / Zimpfer, A.; Went, P.; Tzankov, A.; Pehrs, A. C.; Lugli, A.; Maurer, R.; Terracciano, L.; Pileri, S.; Dirnhofer, Stephan.

In: Histopathology, Vol. 45, No. 4, 10.2004, p. 398-404.

Research output: Contribution to journalArticle

Zimpfer, A, Went, P, Tzankov, A, Pehrs, AC, Lugli, A, Maurer, R, Terracciano, L, Pileri, S & Dirnhofer, S 2004, 'Rare expression of KIT (CD117) in lymphomas: A tissue microarray study of 1166 cases', Histopathology, vol. 45, no. 4, pp. 398-404. https://doi.org/10.1111/j.1365-2559.2004.01968.x
Zimpfer, A. ; Went, P. ; Tzankov, A. ; Pehrs, A. C. ; Lugli, A. ; Maurer, R. ; Terracciano, L. ; Pileri, S. ; Dirnhofer, Stephan. / Rare expression of KIT (CD117) in lymphomas : A tissue microarray study of 1166 cases. In: Histopathology. 2004 ; Vol. 45, No. 4. pp. 398-404.
@article{97c855f88d27487c843d9fdae48258f1,
title = "Rare expression of KIT (CD117) in lymphomas: A tissue microarray study of 1166 cases",
abstract = "Aims: Imatinib mesylate specifically inhibits KIT tyrosine kinase activity, and has been proven to be effective in the treatment of gastrointestinal stromal tumours. Because other KIT-expressing malignancies might benefit from Imatinib therapy, we evaluated the distribution and expression of KIT in 1166 cases of malignant lymphoma. Materials and results: Tissue microarrays (TMAs) containing 824 non-Hodgkin's lymphoma (NHL) and 342 Hodgkin's lymphoma (HL) cases were immunohistochemically analysed for the expression of the KIT protein. Two KIT-positive NHLs were sequenced using polymerase chain reaction analysis. One T-cell lymphoma and one follicular lymphoma of the 747 NHL cases (0.3{\%}) were positive for KIT. All HLs were Kit-negative. None of the KIT-positive cases showed a kit gene mutation. Conclusions: KIT expression is a very rare event in NHL and virtually absent in HL. In the few positive cases, the aberrant expression is not caused by a mutation in the 'hot-spots' of the kit gene, indicating that treatment of these tumours with Imatinib may be ineffective.",
keywords = "CD117, Hodgkin's lymphoma, KIT, Non-Hodgkin's lymphoma, Tissue microarray",
author = "A. Zimpfer and P. Went and A. Tzankov and Pehrs, {A. C.} and A. Lugli and R. Maurer and L. Terracciano and S. Pileri and Stephan Dirnhofer",
year = "2004",
month = "10",
doi = "10.1111/j.1365-2559.2004.01968.x",
language = "English",
volume = "45",
pages = "398--404",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Rare expression of KIT (CD117) in lymphomas

T2 - A tissue microarray study of 1166 cases

AU - Zimpfer, A.

AU - Went, P.

AU - Tzankov, A.

AU - Pehrs, A. C.

AU - Lugli, A.

AU - Maurer, R.

AU - Terracciano, L.

AU - Pileri, S.

AU - Dirnhofer, Stephan

PY - 2004/10

Y1 - 2004/10

N2 - Aims: Imatinib mesylate specifically inhibits KIT tyrosine kinase activity, and has been proven to be effective in the treatment of gastrointestinal stromal tumours. Because other KIT-expressing malignancies might benefit from Imatinib therapy, we evaluated the distribution and expression of KIT in 1166 cases of malignant lymphoma. Materials and results: Tissue microarrays (TMAs) containing 824 non-Hodgkin's lymphoma (NHL) and 342 Hodgkin's lymphoma (HL) cases were immunohistochemically analysed for the expression of the KIT protein. Two KIT-positive NHLs were sequenced using polymerase chain reaction analysis. One T-cell lymphoma and one follicular lymphoma of the 747 NHL cases (0.3%) were positive for KIT. All HLs were Kit-negative. None of the KIT-positive cases showed a kit gene mutation. Conclusions: KIT expression is a very rare event in NHL and virtually absent in HL. In the few positive cases, the aberrant expression is not caused by a mutation in the 'hot-spots' of the kit gene, indicating that treatment of these tumours with Imatinib may be ineffective.

AB - Aims: Imatinib mesylate specifically inhibits KIT tyrosine kinase activity, and has been proven to be effective in the treatment of gastrointestinal stromal tumours. Because other KIT-expressing malignancies might benefit from Imatinib therapy, we evaluated the distribution and expression of KIT in 1166 cases of malignant lymphoma. Materials and results: Tissue microarrays (TMAs) containing 824 non-Hodgkin's lymphoma (NHL) and 342 Hodgkin's lymphoma (HL) cases were immunohistochemically analysed for the expression of the KIT protein. Two KIT-positive NHLs were sequenced using polymerase chain reaction analysis. One T-cell lymphoma and one follicular lymphoma of the 747 NHL cases (0.3%) were positive for KIT. All HLs were Kit-negative. None of the KIT-positive cases showed a kit gene mutation. Conclusions: KIT expression is a very rare event in NHL and virtually absent in HL. In the few positive cases, the aberrant expression is not caused by a mutation in the 'hot-spots' of the kit gene, indicating that treatment of these tumours with Imatinib may be ineffective.

KW - CD117

KW - Hodgkin's lymphoma

KW - KIT

KW - Non-Hodgkin's lymphoma

KW - Tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=6044252858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6044252858&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2559.2004.01968.x

DO - 10.1111/j.1365-2559.2004.01968.x

M3 - Article

VL - 45

SP - 398

EP - 404

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 4

ER -